The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OPCH | -6.22% | +97.24% | +14.53% | +152% |
| S&P | +16.9% | +95.99% | +14.39% | +135% |
Option Care Health, Inc. engages in the provision of home and alternate site infusion services. The firm provides infusion therapy and other ancillary healthcare services through a national network of full-service pharmacies. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Its home infusion services consist of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions. The company was founded in 1996 and is headquartered in Bannockburn, IL.
Option Care Health fell despite posting strong quarterly results. Here's what investors need to know.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.42B | 15.4% |
| Gross Profit | $252.80M | 7.8% |
| Gross Margin | 17.85% | -1.3% |
| Market Cap | $5.32B | 10.5% |
| Market Cap / Employee | $0.88M | 0.0% |
| Employees | 6K | 3.5% |
| Net Income | $50.52M | -4.8% |
| EBITDA | $99.66M | 3.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $198.82M | -47.2% |
| Accounts Receivable | $481.25M | 2.8% |
| Inventory | 403.5 | 43.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.20B | 0.2% |
| Short Term Debt | $29.82M | 4.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.28% | -0.1% |
| Return On Invested Capital | 6.05% | 2.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $81.24M | -56.3% |
| Operating Free Cash Flow | $90.33M | -53.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 26.20 | 18.91 | 27.92 | 25.88 | 11.49% |
| Price to Book | 3.80 | 2.77 | 4.14 | 3.94 | 16.87% |
| Price to Sales | 1.13 | 0.79 | 1.12 | 0.99 | -5.57% |
| Price to Tangible Book Value | -12.00 | -9.32 | -13.30 | -8.98 | -18.31% |
| Price to Free Cash Flow TTM | 18.36 | 13.70 | 16.86 | 22.11 | -10.63% |
| Enterprise Value to EBITDA | 61.01 | 45.44 | 72.01 | 63.82 | 8.24% |
| Free Cash Flow Yield | 5.4% | 7.3% | 5.9% | 4.5% | 11.89% |
| Return on Equity | 14.6% | 15.0% | 15.4% | 15.2% | 4.14% |
| Total Debt | $1.22B | $1.22B | $1.22B | $1.23B | 0.26% |
OPCH earnings call for the period ending September 30, 2021.
OPCH earnings call for the period ending June 30, 2021.
OPCH earnings call for the period ending March 31, 2021.
OPCH earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
